Les complications incluent la métastase, la douleur chronique et des problèmes fonctionnels.
ComplicationsLéiomyosarcomeMétastase
#2
Le léiomyosarcome peut-il se propager ?
Oui, il peut se propager à d'autres organes, notamment les poumons et le foie.
MétastaseLéiomyosarcomePropagation
#3
Y a-t-il des risques liés aux traitements ?
Oui, les traitements peuvent entraîner des effets secondaires comme la fatigue et des nausées.
Effets secondairesLéiomyosarcomeTraitements
#4
Comment gérer la douleur liée au léiomyosarcome ?
La gestion de la douleur peut inclure des médicaments, la physiothérapie et des soins palliatifs.
Gestion de la douleurLéiomyosarcomeSoins palliatifs
#5
Le suivi post-traitement est-il crucial ?
Oui, un suivi régulier est essentiel pour surveiller les récidives et gérer les complications.
Suivi post-traitementLéiomyosarcomeRécidive
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque ?
Les facteurs incluent l'exposition à des radiations, des produits chimiques et des antécédents familiaux.
Facteurs de risqueLéiomyosarcomeRadiations
#2
L'âge influence-t-il le risque de léiomyosarcome ?
Oui, le risque augmente généralement avec l'âge, touchant souvent les adultes d'âge moyen.
ÂgeLéiomyosarcomeRisque
#3
Les maladies génétiques sont-elles un facteur ?
Certaines maladies génétiques, comme le syndrome de Li-Fraumeni, augmentent le risque.
Maladies génétiquesLéiomyosarcomeSyndrome de Li-Fraumeni
#4
Le sexe joue-t-il un rôle dans le risque ?
Oui, les femmes sont légèrement plus susceptibles de développer un léiomyosarcome utérin.
SexeLéiomyosarcomeRisque
#5
L'obésité est-elle un facteur de risque ?
Oui, l'obésité peut être associée à un risque accru de certains types de sarcomes, y compris le léiomyosarcome.
ObésitéLéiomyosarcomeRisque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Léiomyosarcome : Questions médicales les plus fréquentes",
"headline": "Léiomyosarcome : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Léiomyosarcome : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-08",
"dateModified": "2025-03-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Léiomyosarcome"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Sarcomes",
"url": "https://questionsmedicales.fr/mesh/D012509",
"about": {
"@type": "MedicalCondition",
"name": "Sarcomes",
"code": {
"@type": "MedicalCode",
"code": "D012509",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.450.795"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Léiomyosarcome",
"alternateName": "Leiomyosarcoma",
"code": {
"@type": "MedicalCode",
"code": "D007890",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Emily Z Keung",
"url": "https://questionsmedicales.fr/author/Emily%20Z%20Keung",
"affiliation": {
"@type": "Organization",
"name": "Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA."
}
},
{
"@type": "Person",
"name": "Anupama Bahadur",
"url": "https://questionsmedicales.fr/author/Anupama%20Bahadur",
"affiliation": {
"@type": "Organization",
"name": "Obstetrics and Gynecology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND."
}
},
{
"@type": "Person",
"name": "Rajlaxmi Mundhra",
"url": "https://questionsmedicales.fr/author/Rajlaxmi%20Mundhra",
"affiliation": {
"@type": "Organization",
"name": "Obstetrics and Gynecology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND."
}
},
{
"@type": "Person",
"name": "Anoosha K Ravi",
"url": "https://questionsmedicales.fr/author/Anoosha%20K%20Ravi",
"affiliation": {
"@type": "Organization",
"name": "Obstetrics and Gynecology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND."
}
},
{
"@type": "Person",
"name": "Poonam Gill",
"url": "https://questionsmedicales.fr/author/Poonam%20Gill",
"affiliation": {
"@type": "Organization",
"name": "Obstetrics and Gynecology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Hemoperfusion in Poisoning and Drug Overdose.",
"datePublished": "2023-06-13",
"url": "https://questionsmedicales.fr/article/37311422",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000526730"
}
},
{
"@type": "ScholarlyArticle",
"name": "Educational Attainment and US Drug Overdose Deaths.",
"datePublished": "2023-10-06",
"url": "https://questionsmedicales.fr/article/37801307",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1001/jamahealthforum.2023.3274"
}
},
{
"@type": "ScholarlyArticle",
"name": "Psychological distress and the risk of drug overdose death.",
"datePublished": "2022-08-31",
"url": "https://questionsmedicales.fr/article/36057284",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jad.2022.08.115"
}
},
{
"@type": "ScholarlyArticle",
"name": "Drug Decriminalization, Fentanyl, and Fatal Overdoses in Oregon.",
"datePublished": "2024-09-03",
"url": "https://questionsmedicales.fr/article/39235814",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1001/jamanetworkopen.2024.31612"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association of drug overdoses and user characteristics of Canada's national mobile/virtual overdose response hotline: the National Overdose Response Service (NORS).",
"datePublished": "2023-09-27",
"url": "https://questionsmedicales.fr/article/37752527",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12889-023-16751-z"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://questionsmedicales.fr/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs par type histologique",
"item": "https://questionsmedicales.fr/mesh/D009370"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs du tissu conjonctif et des tissus mous",
"item": "https://questionsmedicales.fr/mesh/D018204"
},
{
"@type": "ListItem",
"position": 5,
"name": "Sarcomes",
"item": "https://questionsmedicales.fr/mesh/D012509"
},
{
"@type": "ListItem",
"position": 6,
"name": "Léiomyosarcome",
"item": "https://questionsmedicales.fr/mesh/D007890"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Léiomyosarcome - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Léiomyosarcome",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Léiomyosarcome",
"description": "Comment diagnostique-t-on un léiomyosarcome ?\nQuels examens d'imagerie sont utilisés ?\nLe diagnostic nécessite-t-il une biopsie ?\nQuels marqueurs tumoraux sont associés ?\nPeut-on confondre le léiomyosarcome avec d'autres tumeurs ?",
"url": "https://questionsmedicales.fr/mesh/D007890?mesh_terms=Drug+Overdose#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Léiomyosarcome",
"description": "Quels sont les symptômes courants du léiomyosarcome ?\nLe léiomyosarcome provoque-t-il une perte de poids ?\nPeut-on avoir des symptômes respiratoires ?\nLes symptômes varient-ils selon la localisation ?\nY a-t-il des symptômes spécifiques aux femmes ?",
"url": "https://questionsmedicales.fr/mesh/D007890?mesh_terms=Drug+Overdose#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Léiomyosarcome",
"description": "Peut-on prévenir le léiomyosarcome ?\nLes facteurs environnementaux jouent-ils un rôle ?\nY a-t-il des habitudes à éviter ?\nLes antécédents familiaux influencent-ils le risque ?\nLe suivi médical régulier est-il important ?",
"url": "https://questionsmedicales.fr/mesh/D007890?mesh_terms=Drug+Overdose#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Léiomyosarcome",
"description": "Quels traitements sont disponibles pour le léiomyosarcome ?\nLa chirurgie est-elle toujours nécessaire ?\nLa chimiothérapie est-elle efficace ?\nLa radiothérapie est-elle une option ?\nY a-t-il des traitements expérimentaux ?",
"url": "https://questionsmedicales.fr/mesh/D007890?mesh_terms=Drug+Overdose#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Léiomyosarcome",
"description": "Quelles complications peuvent survenir ?\nLe léiomyosarcome peut-il se propager ?\nY a-t-il des risques liés aux traitements ?\nComment gérer la douleur liée au léiomyosarcome ?\nLe suivi post-traitement est-il crucial ?",
"url": "https://questionsmedicales.fr/mesh/D007890?mesh_terms=Drug+Overdose#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Léiomyosarcome",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de léiomyosarcome ?\nLes maladies génétiques sont-elles un facteur ?\nLe sexe joue-t-il un rôle dans le risque ?\nL'obésité est-elle un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D007890?mesh_terms=Drug+Overdose#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on un léiomyosarcome ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'imagerie médicale et la biopsie des tissus affectés."
}
},
{
"@type": "Question",
"name": "Quels examens d'imagerie sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les IRM et les tomodensitométries (CT) sont couramment utilisés pour visualiser la tumeur."
}
},
{
"@type": "Question",
"name": "Le diagnostic nécessite-t-il une biopsie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une biopsie est essentielle pour confirmer la nature maligne de la tumeur."
}
},
{
"@type": "Question",
"name": "Quels marqueurs tumoraux sont associés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de marqueurs spécifiques, mais des tests génétiques peuvent aider."
}
},
{
"@type": "Question",
"name": "Peut-on confondre le léiomyosarcome avec d'autres tumeurs ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être confondu avec d'autres sarcomes ou tumeurs musculaires."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants du léiomyosarcome ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs, des masses visibles et des troubles fonctionnels selon la localisation."
}
},
{
"@type": "Question",
"name": "Le léiomyosarcome provoque-t-il une perte de poids ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une perte de poids inexpliquée peut survenir en raison de la maladie avancée."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes respiratoires ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, si la tumeur se développe dans les poumons, des symptômes respiratoires peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon la localisation ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes dépendent de l'emplacement de la tumeur dans le corps."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux femmes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les femmes peuvent éprouver des symptômes liés à des tumeurs utérines, comme des saignements."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir le léiomyosarcome ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un mode de vie sain peut aider."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certains produits chimiques peut augmenter le risque de léiomyosarcome."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes à éviter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabagisme et l'exposition à des agents cancérigènes peut réduire le risque."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancers peuvent augmenter le risque de léiomyosarcome."
}
},
{
"@type": "Question",
"name": "Le suivi médical régulier est-il important ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi médical régulier peut aider à détecter précocement des anomalies."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour le léiomyosarcome ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chirurgie, la chimiothérapie et la radiothérapie."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle toujours nécessaire ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie est souvent nécessaire pour retirer la tumeur, selon sa taille et son emplacement."
}
},
{
"@type": "Question",
"name": "La chimiothérapie est-elle efficace ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chimiothérapie peut être utilisée, mais son efficacité varie selon les cas."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle une option ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la radiothérapie peut être utilisée pour traiter les tumeurs inopérables ou résiduelles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des essais cliniques peuvent proposer des traitements expérimentaux pour le léiomyosarcome."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la métastase, la douleur chronique et des problèmes fonctionnels."
}
},
{
"@type": "Question",
"name": "Le léiomyosarcome peut-il se propager ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut se propager à d'autres organes, notamment les poumons et le foie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques liés aux traitements ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent entraîner des effets secondaires comme la fatigue et des nausées."
}
},
{
"@type": "Question",
"name": "Comment gérer la douleur liée au léiomyosarcome ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion de la douleur peut inclure des médicaments, la physiothérapie et des soins palliatifs."
}
},
{
"@type": "Question",
"name": "Le suivi post-traitement est-il crucial ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est essentiel pour surveiller les récidives et gérer les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'exposition à des radiations, des produits chimiques et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de léiomyosarcome ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente généralement avec l'âge, touchant souvent les adultes d'âge moyen."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques sont-elles un facteur ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies génétiques, comme le syndrome de Li-Fraumeni, augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes sont légèrement plus susceptibles de développer un léiomyosarcome utérin."
}
},
{
"@type": "Question",
"name": "L'obésité est-elle un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité peut être associée à un risque accru de certains types de sarcomes, y compris le léiomyosarcome."
}
}
]
}
]
}
Hemoperfusion (HP) is an extracorporeal blood purification therapy that is used to remove poisons or drugs from the body. This chapter provides a brief overview of the technical aspects and the potent...
Educational attainment in the US is associated with life expectancy. As the opioid crisis worsens, it is critical to understand how overdose death rate trends evolve across education groups....
To investigate the association between educational attainment and overdose death rates, with emphasis on trends during the COVID-19 pandemic....
This cross-sectional study used National Vital Statistics System Mortality Multiple Cause-of-Death data describing overdose death rates in the US by educational attainment from January 1, 2000, to Dec...
Educational attainment, categorized as no high school (HS) diploma, HS diploma (or General Educational Development) but no college, some college but no bachelor's degree, and bachelor's degree or more...
The main outcomes were rates of all overdose deaths, overdose deaths involving opioids, and overdose deaths involving synthetic opioids....
Of 912 057 overdose deaths with education information from 2000 to 2021 (mean [SD] age at death, 44.9 [12.3] years; 64.1% male), there were 625 400 deaths (68.6%) among individuals with no college edu...
In this cross-sectional study, lower educational attainment was found to be associated with higher growth in overdose deaths. As the opioid crisis has transitioned to fentanyl and polysubstance use, o...
Previous research has shown an association between psychological distress and overdose death among specific populations. However, few studies have examined this relationship in a large US population-b...
Data from the 2010-2018 NHIS were linked to mortality data from the National Death Index through 2019. Psychological distress was measured using the Kessler 6 scale. Drug overdose deaths were examined...
The study population included 272,561 adults. Adjusting for demographic covariates and using no psychological distress as the reference, distress level was positively associated with the risk of overd...
Limited substance use information prevented adjustment for this potentially important covariate....
Adults with psychological distress were at greater risk of drug overdose death, relative to those without psychological distress. Adults with psychological distress were also at increased risk of deat...
With the implementation of Measure 110 (M110) in 2021, Oregon became the first US state to decriminalize small amounts of any drug for personal use. To date, no analysis of the association of this law...
To evaluate whether the decriminalization of drug possession in Oregon was associated with changes in fatal drug overdose rates after accounting for the rapid spread of fentanyl in Oregon's unregulate...
In this cohort study, the association between fatal overdose and enactment of M110 was analyzed using a matrix completion synthetic control method. The control group consisted of the 48 US states and ...
Measure 110 took effect in Oregon on February 1, 2021....
The primary outcome assessed was fatal drug overdose rates per half-year. A changepoint analysis also determined when each state experienced a rapid escalation of fentanyl in its unregulated drug mark...
In this analysis, rapid spread of fentanyl in Oregon's unregulated drug supply occurred in the first half of 2021, contemporaneous with enactment of M110. A positive crude association was found betwee...
In this cohort study of fatal drug overdose and the spread of fentanyl through Oregon's unregulated drug market, no association between M110 and fatal overdose rates was observed. Future evaluations o...
Several novel overdose response technology interventions, also known as mobile overdose response services (MORS), have emerged as adjunct measures to reduce the harms associated with the drug poisonin...
A retrospective analysis was conducted using NORS call logs from December 2020 to April 2023 imputed by operators. A variety of variables were examined including demographics, substance use and route,...
Of the 6528 completed calls on the line, 3994 (61.2%) were for supervised drug consumption, 1703 (26.1%) were for mental health support, 354 (5.42%) were for harm reduction education or resources, and...
NORS presents a complimentary opportunity to access harm reduction services for individuals that prefer to use alone or face barriers to accessing in-person supervised consumption services especially ...
Death certificates provide incomplete information on the specific drug categories involved in fatal overdoses. The accuracy of previously developed corrections for this and modifications to them was e...
Data were obtained for the universe of 932,364 drug overdoses in the U.S. between 1999 and 2020, including 769,982 (82.6%) with a drug classification and 162,382 (17.4%) without, from the National Cen...
Previous regression-based corrections that controlled for decedent characteristics can be improved upon by adding state-fixed effects as covariates. Once this is done, supplementary controls for count...
Failing to correct for incomplete information on death certificates leads to inaccurate counts of deaths from specific categories of drugs, such as opioids. However, relatively simple corrections are ...
U.S. drug-related overdose deaths and Emergency Department (ED) visits rose in 2020 and again in 2021. Many academic studies and the news media attributed this rise primarily to increased drug use res...
We use national data from the Centers for Disease Control and Prevention (CDC) on rolling 12-month drug-related deaths (2015-2021); CDC data on monthly ED visits (2019-September 2020) for EDs in 42 st...
Mortality. National overdose mortality increased from 21/100,000 in 2019 to 26/100,000 in 2020 and 30/100,000 in 2021. The rise in mortality began in mid-to-late half of 2019, and the 2020 increase is...
The reasons for rising overdose mortality in 2020 and 2021 cannot be definitely determined. We lack a control group and thus cannot assess causation. However, the observed increases can be largely exp...
This study estimated years of life lost (YLL) among US Latinx individuals during the most recent wave of drug overdose deaths....
A serial cross-sectional study of YLL (life expectancy minus age at death) from death certificate records of Latinx individuals who died from drug overdoses from 2015 to mid-2022....
Over the study period, 58,209 Latinx individuals aged 15-64 years died from drug overdoses resulting in 2,266,784 YLL. Age-group YLL differences remained stable, but gender YLL trajectories diverged....
This study extends our understanding of the immense loss to Latinx communities from preventable drug deaths....
Pharmaceutical opioid dosage forms are commonly misused via an oral route in non-manipulated form, i.e., overdose in intact form, or manipulated form, i.e., after crushing the dosage form, and also vi...
Slow and incremental changes in federal and state drug policies are neither meeting treatment needs nor reversing yearly increases in drug-related mortality. U.S. drug policies convey confounding mess...